While President Donald Trump's signature on the FDA Reauthorization Act (FDARA) Friday put to rest any lingering fears about potential layoffs at the FDA come Oct. 1, it also paved the way for the next congressional showdown – one that could still shutter parts of the FDA and other federal agencies. Read More
